Parabilis Medicines EBIT

Parabilis Medicines (PBLS) currently reports a EBIT of $-170M as of June 2026. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Parabilis Medicines's EBIT history and peer comparisons.

Parabilis Medicines's EBIT of $-170M is lower than the Healthcare sector average of $23B. That is roughly 100.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Parabilis Medicines reported $-170M in EBIT as of June 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-170M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Parabilis Medicines, and consider following PBLS for alerts when major investors trade the stock.

Parabilis Medicines is classified in the Healthcare sector. On EBIT, it currently shows $-170M versus a sector average near $23B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PBLS with unrelated industries.